Diurnal Group PLC (LON:DNL) insider John Goddard acquired 10,791 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was bought at an average cost of GBX 540 ($7.22) per share, for a total transaction of £58,271.40 ($77,913.36).
Diurnal Group PLC (DNL) traded up GBX 7 ($0.09) on Friday, reaching GBX 165 ($2.21). 14,121 shares of the company traded hands, compared to its average volume of 2,749. The company has a market cap of $105.42 and a PE ratio of -916.67. Diurnal Group PLC has a 1-year low of GBX 105 ($1.40) and a 1-year high of GBX 165 ($2.21).
Separately, Numis Securities reaffirmed a “buy” rating and issued a GBX 185 ($2.47) price objective on shares of Diurnal Group in a research report on Monday, December 18th.
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.